Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites

Human leukemias with 11q23 translocations occur sporadically and after cancer treatment with DNA topoisomerase II-targeted drugs. To investigate this process, we examined DNA topoisomerase II cleavage in vitro in subclones of the normal 11q23 genomic homologue and a t(9;11) translocation breakpoint...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1995-10, Vol.55 (19), p.4287-4292
Main Authors: FELIX, C. A, LANGE, B. J, HOSLER, M. R, FERTALA, J, BJORNSTI, M.-A
Format: Article
Language:English
Subjects:
Base Sequence
Biological and medical sciences
Chromosomes, Human, Pair 11
Chromosomes, Human, Pair 9
DNA Topoisomerases, Type II - physiology
DNA-Binding Proteins - genetics
Drug toxicity and drugs side effects treatment
Histone-Lysine N-Methyltransferase
Humans
Introns
Medical sciences
Miscellaneous (drug allergy, mutagens, teratogens...)
Molecular Sequence Data
Myeloid-Lymphoid Leukemia Protein
Pharmacology. Drug treatments
Proto-Oncogenes
Transcription Factors
Translocation, Genetic
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human leukemias with 11q23 translocations occur sporadically and after cancer treatment with DNA topoisomerase II-targeted drugs. To investigate this process, we examined DNA topoisomerase II cleavage in vitro in subclones of the normal 11q23 genomic homologue and a t(9;11) translocation breakpoint junction. Cleavage was assayed with limiting dilutions of enzyme in the presence or absence of epipodophyllotoxin and ATP. The strongest sites of cleavage coincided with the t(9;11) breakpoint site and two other translocation breakpoint sites within the normal homologue. These results support the involvement of DNA topoisomerase II in the translocation process at chromosome band 11q23.
ISSN:0008-5472
1538-7445